Drug combination shows effectiveness in patients with recurrent ER-positive endometrial cancer (Cancer was stopped or regressed in 75% of patients)

Medical Xpress / Dana-Farber Cancer Institute / Society of Gynecologic Oncology ^ | Mar. 20, 2022 | Panagiotis Konstantinopoulos, MD, Ph.D. et al

[ConservativeMind]

A combination therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in 75% of patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer.

The phase 2 study evaluated the combination of abemaciclib, a targeted drug, and letrozole, an aromatase inhibitor, in 30 patients with recurrent ER-positive endometrial cancer, a form of the disease in which tumor growth is fueled by estrogen. The patients had received a median of three prior therapies, and about half of them had been treated with hormonal therapy.

With a median follow-up of 12.5 months, 75% of the patients had their tumors shrink or become stable. About 30% of the participants had their tumors shrink by more than 30%. The benefits were persistent: the median time before the disease began to worsen was 9.1 months.

"When we compare the efficacy of this regimen with that of other endocrine therapies for endometrial cancer, we can see this combination is extremely promising," says Panagiotis Konstantinopoulos, MD, Ph.D. "Our findings suggest it will be a very effective alternate endocrine therapy for patients with recurrent endometrial cancer whose tumors express the estrogen receptor."

Letrozole works by preventing an enzyme in fat tissue from converting certain hormones into estrogen, thereby lowering overall estrogen levels. Abemaciclib blocks the CDK4 and CDK6 proteins, which play a key role in cell proliferation. Combining these agents provides a two-pronged attack on ER-positive endometrial cancer cells.

Analysis of patients' tumor tissue showed that responses to the regimen occurred regardless of a tumor's grade (how abnormal its cells look under a microscope), prior treatment with hormonal therapy, or the presence or absence of progesterone receptors on tumor cells. All patients whose tumor cells harbored mutations in the KRAS, CTNNB1 or CDK2NA genes responded to the therapy.

[ConservativeMind]

This appears to work on recurring cancers.

[ConservativeMind]

The “Take Charge Of Your Health” Ping List

This potentially high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to implement for your benefit.

Now keeping a new list (“Common Issues”) for conditions expected to only concern at least 1% of the population. Ask to be on either the “Common Issues” or “Everything” list.

Please email or private message me if you want on or off of a list and of which list you desire.

[Nateman]

Defeating Cancer is very close to defeating the aging process itself. Cells are programmed to die after a certain number of divisions as a natural protection against Cancer . The problem is that death is certain because cells can't be replaced after a certain point.

Imagine Swamp critters in the District of Corruption who will no longer do us the favor of dying anymore .

[ptsal]

bkmk